Pipeline Expansion And Label Extension Will Broaden Treatment Options
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
05 May 25
Updated
24 Jul 25
AnalystConsensusTarget's Fair Value
US$6.38
84.0% undervalued intrinsic discount24 Jul
US$1.02
1Y
-12.8%7D
-2.9%